Journal: Oncology Letters

Article Title: Scutellarein suppresses Aβ-induced memory impairment via inhibition of the NF-κB pathway in vivo and in vitro

doi: 10.3892/ol.2019.10274

Figure Lengend Snippet: Scue attenuates Alzheimer's disease-like pathology in rats. (A) Latency of crossings and (B) average number of crossings in the Morris water maze spatial probe test of memory. Hippocampal expression of (C) Aβ, (D) SOD, (E) MDA and (F) Ach. (G) Nissl staining in the hippocampus. Scale bar, 50 µm. The expression levels of (H) Bcl-2, Bax and cleaved-caspase-3 were detected by western blotting. Densitometry analyses were conducted using β-actin as an internal reference. Representative results from repeated experiments are presented and data are presented as the mean ± standard deviation. n=6. **P<0.01, ***P<0.001 vs. the control group; # P<0.05, ## P<0.01, ### P<0.001 vs. the Aβ group. ^ P<0.05, ^^ P<0.01 vs. the Scu group. Aβ, amyloid β; Scu, scutellarin; Scue, scutellarein; SOD, superoxide dismutase; MDA, malondialdehyde; Ach, acetylcholine; Bcl-2, B cell lymphoma-2; Bax, apoptosis regulator BAX.

Article Snippet: The membranes were incubated with primary antibodies against nuclear factor of κ-light polypeptide gene enhancer in B cells inhibitor α [IκBα; cat. no. YS-(kt)-0907, phospho (p)-IκBα (cat. no. YS-KT1551) (Shanghai Yansheng Biochemical Reagent Co., Ltd., Shanghai, China), NF-κB, cleaved caspase-3 (cat. no. bs-0081R), B cell lymphoma-2 (Bcl-2; cat. no. bs-20351R), apoptosis regulator BAX (Bax; cat. no. bs-4564R), β-actin (cat. no. bs-0061R) and lamin-A (cat. no. bs-1839R) (1:1,000; BIOSS) overnight at 4°C.

Techniques: Expressing, Staining, Western Blot, Standard Deviation

Journal: Oncology Letters

Article Title: Treatment with a selenium-platinum compound induced T-cell acute lymphoblastic leukemia/lymphoma cells apoptosis through the mitochondrial signaling pathway

doi: 10.3892/ol.2017.5666

Figure Lengend Snippet: Change in expression of genes associated with cell apoptosis in Jurkat and Molt-4 cells. (A) Jurkat and Molt-4 cells were treated with the indicated concentrations of EG-Se/Pt for 24 h. (B) Jurkat and Molt-4 cells were treated with 15 and 12.5 µM EG-Se/Pt, respectively, for 24, 48 and 72 h. Whole-cell, mitochondrial and cytosolic extracts were processed for western blotting using anti-Bcl-2, anti-Bax, anti-cleaved caspase-9, anti-caspase-3 and anti-cleaved PARP antibodies, and mitochondrial and cytosolic extracts were processed for western blotting using anti-cytochrome c antibody. β-actin served as a loading control. The expression of Bax, cytosolic cytochrome c , Apaf-1, cleaved caspase-9, cleaved caspase-3 and cleaved PARP visibly increased, and the expression of Bcl-2 and mitochondrial cytochrome c visibly decreased in a dose- and time-dependent manner in the EG-Se/Pt-treated cell lines (P<0.05). Bcl-2, apoptosis regulator Bcl-2; Bax, apoptosis regulator Bax; PARP, poly(ADP-ribose) polymerase; Apaf-1, apoptotic protease-activating factor 1.

Article Snippet: Rabbit monoclonal antibodies against apoptosis regulator Bcl-2 (1:1,000; cat. no. 4223) and cleaved caspase-3 (1:1,000; cat. no. 9664), and rabbit polyclonal antibodies against apoptosis regulator Bax (1:1,000; cat. no. 2772), cleaved caspase-9 (1:1,000; cat. no. 9505) and cleaved poly(ADP-ribose) polymerase (PARP; 1:1,000; cat. no. 9542) were from Cell Signaling Technology, Inc. (Danvers, MA, USA).

Techniques: Expressing, Western Blot

Journal: Journal of Inflammation Research

Article Title: NUP62CL as an Immunological and Prognostic Biomarker of Oral Squamous Cell Carcinoma

doi: 10.2147/JIR.S426277

Figure Lengend Snippet: ( A ) The representative mIHC images of PD-1, PD-L1 and CTLA-4 protein expression. ( B ) The PD-1, PD-L1 and CTLA-4 protein expression in NUP62CL high-expression and low-expression groups. The correlation of NUP62CL protein expression with the immune checkpoints in OSCC tissues, including PD-1 ( C ), PD-L1 ( D ) and CTLA-4 ( E ). * P <0.05, *** P <0.001.

Article Snippet: Details of the antibodies used in this study are as follows: anti-NUP62CL (1:500, orb312372, Biorbyt, UK); anti-cytokeratin (1:4000, orb69073, Biorbyt, UK); anti-CD56 antibody (1: 200, 3576s, CST, USA); anti-CD66b (1:2000, arg66287, Arigo, China); anti-CD68 (1: 2000, 76437s, CST, USA); anti-CD86 (1: 200, orb388891, Biorbyt, UK); anti-CD163 (1: 400, 93498s, CST, USA); anti-CD3 antibody (1: 400, 85061s, CST, USA); anti-CD4 (1:50, ab133616, Abcam, USA); anti-CD8 (1: 200, 85336s, CST, USA); anti-PD-1 (1:200, 13684T, CST, USA); anti-PD-L1 (1:400, 18616s, CST, USA); anti-CTLA-4 (1:400, orb527271, Biorbyt, UK).

Techniques: Expressing